CJC-1295 (No DAC) vs Tesamorelin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CJC-1295 DAC, CJC-1295 no DAC
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified GHRH(1-29), engineered for a long duration of action. The form most people mean by CJC-1295 includes a Drug Affinity Complex (DAC) that binds blood albumin to extend its half-life to roughly 6 to 8 days, raising GH and IGF-I for days from a single injection. It was developed by ConjuChem, reached Phase II trials and was abandoned; it is not an approved drug and is sold only as a research chemical. A version without DAC (Modified GRF 1-29) acts for only about 30 minutes.
Also: Egrifta, Egrifta WR
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH 1-44) with a chemical modification that protects it from rapid breakdown. It is FDA-approved (brand name Egrifta) to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy, which makes it one of the few growth-hormone-axis peptides with a real approval behind it. Its evidence base is solid for that specific population and thinner for the general anti-aging and fat-loss uses it gets promoted for online.
Key Comparison Insights
- Tesamorelin is FDA approved, while CJC-1295 (No DAC) remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Tesamorelin has stronger research evidence (FDA Approved) compared to CJC-1295 (No DAC) (Human Trials).
Detailed Comparison
| Attribute | CJC-1295 (No DAC) | Tesamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | CJC-1295 acts at the GHRH receptor on pituitary somatotroph cells, the same receptor the body's own GHRH uses, prompting the pituitary to synthesize and release growth hormone. Native GHRH is broken down within minutes; CJC-1295 with DAC carries a reactive group that covalently bonds to circulating albumin after injection, shielding it from breakdown and stretching its half-life from minutes to days. The sustained GH elevation drives the liver to produce IGF-I, the downstream hormone behind many of GH's tissue effects. There are two versions: with DAC (long-acting, albumin-binding) and without DAC (Modified GRF 1-29), which lacks the albumin tether. Because it works through the pituitary, it relies on the gland's own GH-producing capacity. | Tesamorelin tells the pituitary gland to release the body's own growth hormone by acting on GHRH receptors, rather than injecting growth hormone directly. Because it works upstream, it produces a more natural, pulsing pattern of growth-hormone release. The molecule is GHRH 1-44 with a trans-3-hexenoic acid group added to the N-terminus, and that modification slows enzymatic degradation so the signal lasts longer than native GHRH. The downstream rise in growth hormone and IGF-1 is what drives the reduction in visceral fat seen in trials. This is a genuinely upstream, receptor-based mechanism, well characterized in human studies. |
| Common Dosing | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) | 2 mg daily (F8: 1.28 mg daily) Once daily |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 8-12 weeks | Indefinite for approved indication |
| Best Time to Take | Before bed | Before bed (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The key human study is Teichman et al. (2006) in the Journal of Clinical Endocrinology and Metabolism, a randomized, double-blind, placebo-controlled ascending-dose trial in healthy adults. A single subcutaneous injection raised mean plasma GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, with cumulative effects on repeat dosing, and was reported as safe and relatively well tolerated short-term. An earlier study showed once-daily CJC-1295 normalized growth in GHRH-knockout mice. Beyond pharmacokinetics and hormone levels, there are no large long-term human trials demonstrating clinical benefits like fat loss or muscle gain, so those claims are not established by published trials. Development was halted after Phase II; a single trial death was attributed by the attending physician to pre-existing coronary artery disease rather than the drug, which is reported but not independently confirmed. Bottom line: the GH and IGF-I-raising effect and long half-life are well supported, while real-world efficacy and long-term safety are not. | The approval rests on real randomized, placebo-controlled human trials. The pivotal study by Falutz and colleagues (New England Journal of Medicine, 2007) showed that six months of tesamorelin selectively reduced visceral abdominal fat in HIV patients while improving lipid profiles, without meaningful harm to blood sugar control. Later randomized work (including a JAMA-published trial led by Stanley) confirmed reductions in visceral fat and liver fat. A small placebo-controlled study in non-HIV adults with abdominal obesity also found a meaningful visceral fat reduction over 26 weeks, hinting at broader potential, though that is far less established than the HIV indication. Side effects can include joint pain, swelling, and increases in IGF-1, and growth-hormone-axis drugs warrant caution in people with cancer history or uncontrolled diabetes. In short: well proven for HIV-associated visceral fat, promising but not approved for general use. |
Frequently Asked Questions: CJC-1295 (No DAC) vs Tesamorelin
What is the difference between CJC-1295 (No DAC) and Tesamorelin?
CJC-1295 (No DAC) is a growth hormone peptide that cjc-1295 is a synthetic analog of growth hormone-releasing hormone (ghrh), specifically a modified ghrh(1-29), engineered for a long duration of action. the form most people mean by cjc-1295 includes a drug affinity complex (dac) that binds blood albumin to extend its half-life to roughly 6 to 8 days, raising gh and igf-i for days from a single injection. it was developed by conjuchem, reached phase ii trials and was abandoned; it is not an approved drug and is sold only as a research chemical. a version without dac (modified grf 1-29) acts for only about 30 minutes. Tesamorelin is a growth hormone peptide that tesamorelin is a stabilized analog of growth-hormone-releasing hormone (ghrh 1-44) with a chemical modification that protects it from rapid breakdown. it is fda-approved (brand name egrifta) to reduce excess visceral abdominal fat in people with hiv-associated lipodystrophy, which makes it one of the few growth-hormone-axis peptides with a real approval behind it. its evidence base is solid for that specific population and thinner for the general anti-aging and fat-loss uses it gets promoted for online. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CJC-1295 (No DAC) or Tesamorelin?
Neither is universally "better" - the choice depends on your specific goals. CJC-1295 (No DAC) is typically used for growth hormone purposes, while Tesamorelin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CJC-1295 (No DAC) and Tesamorelin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CJC-1295 (No DAC) and Tesamorelin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.